Stellarex drug-coated balloon for treatment of femoropopliteal disease: Twelve-month outcomes from the randomized ILLUMENATE pivotal and pharmacokinetic studies

Circulation

Volumn 136, Issue 12, 2017, Pages 1102-1113

  Krishnan, Prakash ^a,n   Faries, Peter ^a   Niazi, Khusrow ^b   Jain, Ash ^c   Sachar, Ravish ^d   Bachinsky, William B ^e   Cardenas, Joseph ^f   Werner, Martin ^g   Brodmann, Marianne ^h   Mustapha, J A ⁱ   Mena Hurtado, Carlos ^j   Jaff, Michael R ^k   Holden, Andrew H ^l   Lyden, Sean P ^m  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

^c Mission Cardiovascular Research Institute   (United States)

^d UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^e Harrisburg Hospital   (United States)

^f Yuma Regional Medical Center   (United States)

^g HANUSCH HOSPITAL   (Austria)

^h MEDICAL UNIVERSITY OF GRAZ   (Austria)

ⁱ Metro Health Hospital   (United States)

^j YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l AUCKLAND CITY HOSPITAL   (New Zealand)

^m LERNER RESEARCH INSTITUTE   (United States)

ⁿ MOUNT SINAI MEDICAL CENTER   (United States)

more..

Author keywords

Angioplasty; Drugeluting balloon; Femoropopliteal; Intermittent claudication; Paclitaxel; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; TICLOPIDINE; BIOCOMPATIBLE COATED MATERIAL; CARDIOVASCULAR AGENT;

AGED; ANKLE BRACHIAL INDEX; AREA UNDER THE CURVE; ARTICLE; CALCIFICATION; CLINICAL OUTCOME; COHORT ANALYSIS; CONTROLLED STUDY; DEVICE SAFETY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG CLEARANCE; DRUG COATING; FEMALE; FEMOROPOPLITEAL DISEASE; HUMAN; KAPLAN MEIER METHOD; LEG AMPUTATION; LEG DISEASE; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY BALLOON; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TARGET LESION REVASCULARIZATION; TREATMENT DURATION; BLOOD; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECTS; FEMORAL ARTERY; HALF LIFE TIME; MIDDLE AGED; MORTALITY; PATHOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL ARTERIAL DISEASE; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME; VASCULAR PATENCY;

AGED; ANGIOPLASTY, BALLOON; CARDIOVASCULAR AGENTS; COATED MATERIALS, BIOCOMPATIBLE; FEMALE; FEMORAL ARTERY; HALF-LIFE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PACLITAXEL; PERIPHERAL ARTERIAL DISEASE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD; TIME FACTORS; TREATMENT OUTCOME; VASCULAR PATENCY;

EID: 85026201360     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.028893     Document Type: Article

References (24)

1. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015;116:1509-1526. doi: 10.1161/CIRCRESAHA.116.303849.
2. Criqui MH, Browner D, Fronek A, Klauber MR, Coughlin SS, Barrett-Connor E, Gabriel S. Peripheral arterial disease in large vessels is epidemiologically distinct from small vessel disease. An analysis of risk factors. Am J Epidemiol. 1989;129:1110-1119.
3. Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer A, Shishehbor MH, Stewart KJ, Treat-Jacobson D, Walsh ME. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e686-e725. doi: 10.1161/CIR.0000000000000470.
4. Matsumura JS, Yamanouchi D, Goldstein JA, Pollock CW, Bosiers M, Schultz GA, Scheinert D, Rocha-Singh KJ. The United States study for evaluating endovascular treatments of lesions in the superficial femoral artery and proximal popliteal by using the Protégé EverfLex Nitinol Stent System II (DURABILITY II). J Vasc Surg. 2013;58:73-83.e1. doi: 10.1016/j.jvs.2012.12.066.
5. Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, Dave R, Ansel G, Lansky A, Cristea E, Collins TJ, Goldstein J, Cao AY, Jaff MR; RESILIENT Investigators. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19:1-9. doi: 10.1583/11-3627.1.
6. Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, Metzger C, Scheinert D, Zeller T, Cohen DJ, Snead DB, Alexander B, Landini M, Jaff MR; IN.PACT SFA Trial Investigators. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495-502. doi: 10.1161/CIRCULATIONAHA.114.011004.
7. Rosenfield K, Jaff MR, White CJ, Rocha-Singh K, Mena-Hurtado C, Metzger DC, Brodmann M, Pilger E, Zeller T, Krishnan P, Gammon R, Müller-Hülsbeck S, Nehler MR, Benenati JF, Scheinert D; LEVANT 2 Investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145-153. doi: 10.1056/NEJMoa1406235.
8. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Zeller T, Roubin GS, Burket MW, Khatib Y, Snyder SA, Ragheb AO, White JK, Machan LS; Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495-504. doi: 10.1161/CIRCINTERVENTIONS.111.962324.
9. Laird JR, Schneider PA, Tepe G, Brodmann M, Zeller T, Metzger C, Krishnan P, Scheinert D, Micari A, Cohen DJ, Wang H, Hasenbank MS, Jaff MR; IN.PACT SFA Trial Investigators. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66:2329-2338. doi: 10.1016/j.jacc.2015.09.063.
10. Iida O, Nanto S, Uematsu M, Ikeoka K, Okamoto S, Nagata S. Influence of stent fracture on the long-term patency in the femoro-popliteal artery: experience of 4 years. JACC Cardiovasc Interv. 2009;2:665-671. doi: 10.1016/j.jcin.2009.04.014.
11. Scheinert D, Scheinert S, Sax J, Piorkowski C, Bräunlich S, Ulrich M, Biamino G, Schmidt A. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312-315. doi: 10.1016/j.jacc.2004.11.026.
12. Tosaka A, Soga Y, Iida O, Ishihara T, Hirano K, Suzuki K, Yokoi H, Nanto S, Nobuyoshi M. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol. 2012;59:16-23. doi: 10.1016/j.jacc.2011.09.036.
13. Jaff MR. Drug-coated balloon treatment for patients with intermittent claudication: insights from the IN.PACT Global Full Clinical Cohort. Paper presented at: Vascular InterVentional Advances (VIVA) 2016; September 19-20, 2016; Las Vegas, NV.
14. Schroeder H, Meyer DR, Lux B, Ruecker F, Martorana M, Duda S. Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first-in-human study. Catheter Cardiovasc Interv. 2015;86:278-286. doi: 10.1002/ccd.25900.
15. Schroeder H, Werner M, Meyer DR, Reimer P, Krüger K, Jaff MR, Brodmann M; ILLUMENATE EU RCT Investigators. Low-dose paclitaxel- coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease: one-year results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon). Circulation. 2017;135:2227-2236. doi: 10.1161/CIRCULATIONAHA.116.026493.
16. Lutonix 035 Drug Coated Balloon PTA Catheter Instructions for Use. https://www.accessdata.fda.gov/cdrh-docs/pdf13/P130024d.pdf. Accessed May 2017.
17. Fanelli F, Cannavale A, Gazzetti M, Lucatelli P, Wlderk A, Cirelli C, d'Adamo A, Salvatori FM. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol. 2014;37:898-907. doi: 10.1007/s00270-014-0904-3.
18. Tepe G, Beschorner U, Ruether C, Fischer I, Pfaffinger P, Noory E, Zeller T. Drug-eluting balloon therapy for femoropopliteal occlusive disease: predictors of outcome with a special emphasis on calcium. J Endovasc Ther. 2015;22:727-733. doi: 10.1177/1526602815600156.
19. Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014;83:E212-E220. doi: 10.1002/ccd.25387.
20. Dattilo R, Himmelstein SI, Cuff RF. The COMPLIANCE 360° Trial: a randomized, prospective, multicenter, pilot study comparing acute and long-term results of orbital atherectomy to balloon angioplasty for calcified femoropopliteal disease. J Invasive Cardiol. 2014;26:355-360.
21. Patel MR, Conte MS, Cutlip DE, Dib N, Geraghty P, Gray W, Hiatt WR, Ho M, Ikeda K, Ikeno F, Jaff MR, Jones WS, Kawahara M, Lookstein RA, Mehran R, Misra S, Norgren L, Olin JW, Povsic TJ, Rosenfield K, Rundback J, Shamoun F, Tcheng J, Tsai TT, Suzuki Y, Vranckx P, Wiechmann BN, White CJ, Yokoi H, Krucoff MW. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). J Am Coll Cardiol. 2015;65:931-938 doi: 10.1016/j.jacc.2014.12.036.
22. Granada JF, Stenoien M, Buszman PP, Tellez A, Langanki D, Kaluza GL, Leon MB, Gray W, Jaff MR, Schwartz RS. Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing. Open Heart. 2014;1:e000117. doi: 10.1136/openhrt-2014-000117.
23. Mark J, Ngai K, Graessley WW, Mandelkern L, Samulski E, Koenig J, Wignall G. Physical Properties of Polymers. 3rd ed. Cambridge, United Kingdom: Cambridge University Press; 2004.
24. Venkatasubba GD, Ramasamy S, Avadhani GS, Ramakrishnan V, Kumar J. Surface modification and paclitaxel drug delivery of folic acid modified polyethylene glycol functionalized hydroxyapatite nanoparticles. Powder Technol. 2013;235:437-442.